• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Glucose monitoring company LifeScan files chapter 11 to reduce debt

July 17, 2025 By Sean Whooley

LifeScan OneTouch appLifeScan announced that it entered into a restructuring support agreement and, to implement it, filed for chapter 11 bankruptcy.

The company filed voluntary petitions for prearranged chapter 11 cases in the United States Bankruptcy Court for the Southern District of Texas. It made this move to implement its restructuring agreement with its first- and second-lien lenders and current equity sponsor as efficiently as possible.

Malvern, Pennsylvania-based LifeScan expects to emerge from the process under the majority ownership of a group of existing lenders. It plans for the restructuring to “transform its balance sheet” while positioning it for a stronger, more profitable future. The company expects to reduce more than 75% of its debt to accelerate strategic investments that support its future.

As the process moves forward, LifeScan plans to operate in the ordinary course of business. It expects to emerge from chapter 11 by the end of the year.

LifeScan develops the OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app that provide simplicity, accuracy and trust in diabetes management.

“This balance sheet restructuring will significantly strengthen LifeScan’s financial position, enabling us to continue serving more than 20 million customers across 50+ countries and put new growth strategies in place,” said Valerie Asbury, CEO of LifeScan. “We recognize that our products are essential for people with diabetes to make life-sustaining decisions and are evolving our model to bring products and services to market through multiple channels. I am deeply grateful for the partnership of our lenders and sponsor and the unyielding commitment of our employees, which will enable us to become a stronger company and create a world without limits for people with diabetes.”

Filed Under: Business/Financial News, Diabetes, Patient Monitoring Tagged With: lifescan

IN CASE YOU MISSED IT

  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance
  • Medtronic moves to divest final stake in MiniMed
  • Dexcom adds former Stryker CFO to board
  • MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS